Angiomax Patent Decision, Seven Possible Approvals Mean Catalytic Year For The Medicines Co.
This article was originally published in The Pink Sheet Daily
Executive Summary
While readying an appeal to a patent ruling benefiting Hospira’s efforts to introduce an Angiomax generic, the hospital-care specialist has several drugs nearing regulatory decisions in the U.S. and Europe.
You may also be interested in...
Angiomax Generic From Hospira Might Launch At-Risk Launch In 2015
District Court upholds validity of TMC’s process patents for its anticoagulant but finds Hospira does not infringe them.
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.